[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"opioid-abuse\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:opioid-abuse":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100439729","phase-2-opioidbenzodiazepine-polydrug-abuse-aim-3-100439729",false,"NCT05006079","Opioid\u002FBenzodiazepine Polydrug Abuse: Aim 3","Opioid\u002FBenzodiazepine Polydrug Abuse: Integrating Research on Mechanisms, Treatment and Policies - Study 3","MAP","Inclusion Criteria:\n\n* must self-report past 10-year experience taking opioid and sedative drugs (for therapeutic or non-therapeutic reasons), but not necessarily at the same time. As an alternative to the sedative drug exposure requirement, participants must have used alcohol on at least 3 separate days during the past month. Participants may have current mild- or moderate-severity Opioid Use Disorder or current mild- or moderate-severity Sedative Use Disorder;\n* must not be seeking treatment for their substance use problems;\n* must be in current good overall health\n\nExclusion Criteria:\n\n* meet DSM-5 criteria for current psychosis, bipolar disorder, or severe depression (i.e. severe psychiatric disorder);\n* meet DSM-5 criteria for severe substance use disorder for any substance (e.g. Sedative, Opioid, Alcohol);\n* past-month benzodiazepine or opioid prescription (which would suggest daily use, tolerance, or withdrawal upon cessation);\n* report of past-year any-drug overdose or suicide attempt\u002Fideation;\n* exhibit cognitive impairment (IQ \\\u003C 80 on the Shipley Institute of Living Scale);\n* neurological, cardiovascular, pulmonary, or systemic diseases (see specific exclusionary conditions under Protection of Human Subjects);\n* body mass index \\> 38 kg\u002Fm2;\n* females who are pregnant (urine), lactating or heterosexually active (self-report) and not using medically approved birth control;\n* treatment with methadone, buprenorphine or naltrexone;\n* past 30-day use of contraindicated medications;\n* alcohol-positive breath sample (\\>.02% breath alcohol concentration);\n* urine sample positive for methadone, cocaine, amphetamines, or barbiturates (\\\u003C300 ng\u002Fml)\n* intolerance of lactose","ALL","18 Years","65 Years",{"count":21,"type":22},24,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","In this study, the investigators will measure affective, neurocognitive and behavioral outcomes related to chronic use of opioids and benzodiazepines (screening phase), and in response to the administration of the opioid morphine, the benzodiazepine alprazolam, morphine then alprazolam, alprazolam then morphine, morphine+alprazolam simultaneously, and placebo (laboratory pharmacology experiment). The latter will enable the investigators to assess the effects of an opioid alone, benzodiazepine alone, concurrent and simultaneous administration of opioid+benzodiazepine, relative to a placebo control.",[28,29,30],"Opioid Abuse","Benzodiazepine Abuse","Polysubstance Abuse","RECRUITING","2025-12-26",{"date":34,"type":35},"2025-12-30","ACTUAL",{"date":37,"type":35},"2024-03-13",{"date":39,"type":22},"2026-12",{"name":41,"class":42},"Wayne State University","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":43},"100566142","fmri-and-opioid-abstinence-100566142","NCT06651333","fMRI and Opioid Abstinence","Functional Connectivity Mechanisms of Opioid Abstinence","Inclusion Criteria:\n\n* recent initiation of methadone or buprenorphine at a clinic or program within the past year (i.e., period of time during which treatment drop-out and risk for relapse is highest);\n* eligibility for MRI scanning;\n* ability to commit to study visits.\n\nExclusion Criteria:\n\n* current acute psychosis, mania, or suicidal ideation with intent, as assessed during screening with the SCID-5;\n* current intoxication or acute withdrawal at time of study visit sufficient to prevent participation based on: behavioral observation, breathalyzer, and SOWS assessment;\n* severe cognitive impairment as determined via trained clinical research staff through consent process and during consent quiz or as indicated by a PROMIS Cognitive Function tscore \\\u003C30 (i.e., severe impairment)\n* past or present history of intellectual disability, developmental disorder, or neurological disease;\n* head trauma with loss of consciousness \\>30 min;\n* organ dysfunction or any unstable or untreated medical conditions that may interfere with study participation.","50 Years",{"count":53,"type":22},240,"OBSERVATIONAL","This project examines functional connectivity patterns associated with subsequent relapse to illicit opioids during treatment for OUD.",[57,58,59,60,28],"Drug Use Disorder","Opioid Dependence","Opioid-Related Disorders","Opioid Use",[62],"Relapse","2025-10-16",{"date":65,"type":35},"2025-10-20",{"date":67,"type":35},"2024-12-12",{"date":69,"type":22},"2029-11",{"name":71,"class":42},"Yale University",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":88,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":43},"100493891","rural-expanded-access-to-oud-care--linkage-using-toxicologists-for-telehealth-initiated-treatment-100493891","NCT05711056","Rural Expanded Access to OUD Care & Linkage Using Toxicologists for Telehealth Initiated Treatment","Expanding Rural Access to Opioid Use Disorder Treatment Utilizing Medical Toxicologists and the Georgia Poison Center to Facilitate Emergency Department- and Telehealth-Based Medication Initiation and Linkage to Care","REAL TTIME","Inclusion Criteria:\n\n* Age 18 years or older\n* English speaking\n* Clinically sober\n* Medically and psychiatrically stable\n\nExclusion criteria:\n\n* Already receiving MAT or psychotherapy for OUD prior to ED arrival\n* Prior participation in the study\n* Unable to provide informed consent\n* If their clinical condition worsens such that continued participation would be considered unsafe in the opinion of the PRC or ED staff\n* Prisoners\n* Individuals who are not yet adults (infants, children, teenagers)\n* Cognitively impaired or Individuals with Impaired Decision-Making Capacity\n* Individuals who are not able to clearly understand English",{"count":81,"type":22},480,[83],"NA","The overarching goal of this project is to increase the availability of OUD treatment in rural counties in the state of Georgia by using Emergency Department (ED)-based telehealth strategies to initiate MOUD and connect patients to treatment.\n\nThe investigators will implement a novel collaboration between rural EDs, medical toxicologists at the Georgia Poison Center (GPC), peer recovery coaches (PRCs) and RCOs throughout Georgia to bridge the gap between OUD treatment need in rural EDs and specialty physician availability at the GPC.\n\nResearch activities will be conducted during two broad phases, at three rural EDs in Georgia: planning and implementation. During the planning phase, aggregate data will be obtained to determine each ED's existing practices treating patients with OUD and opioid withdrawal. During the implementation phase, the researchers will prospectively study a poison center OUD consultation and PRC intervention as it is rolled out at each site, collecting participant-level data. Sites will be rolled into the implementation phase in a stepped-wedge fashion, so there will be times when some sites are in the planning phase while others are in the implementation phase.",[60,28],[87],"Opioid",{"date":65,"type":35},{"date":90,"type":35},"2023-08-30",{"date":92,"type":22},"2026-08",{"name":94,"class":42},"Emory University"]